Editor’s Note: From Innovation to a Partner-Ready Asset

Welcome to China Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into credible partnering opportunities.

In this edition, we focus on inhaled anti-fibrotic assets and the factors now shaping buyer and investor decisions—from target biology and patient evidence to drug–device execution, IP protection, CMC readiness and transaction structure. Our aim is to provide asset owners, potential partners and investors with a practical framework for evaluating scientific differentiation and transaction readiness.  

---

1. Why inhaled anti-fibrotic programs are back on the BD agenda

The strategic appeal is straightforward. Lung-directed delivery may create high local exposure while reducing systemic exposure, potentially widening the therapeutic window of either established anti-fibrotic agents or new mechanisms. That logic is especially attractive when oral dosing is constrained by gastrointestinal, hepatic or other systemic adverse effects. But the current market is more demanding than it was a few years ago. In October 2025, FDA approved nerandomilast for idiopathic pulmonary fibrosis (IPF), the first new therapy for IPF in more than a decade; the agency approved it for progressive pulmonary fibrosis (PPF) in December 2025. Meanwhile, multiple inhaled programs are in patient-stage development. Local delivery is therefore a credible development strategy, but it is no longer sufficient differentiation by itself.

Figure 1  |  Evidence ladder: the value inflection sits in patient pharmacology and controlled proof, not in delivery concept alone.

BD IMPLICATION  Frame an inhaled portfolio around the evidence-bearing lead product. Treat follow-on indications, oral analogues and platform claims as options until they have their own translational bridge and execution plan.

 

What buyers are underwriting

• A clinically relevant lung exposure advantage—not simply lower plasma concentrations.
• A differentiated efficacy, safety, combination or treatment-burden profile versus current oral therapy.
• A commercial device and manufacturing package that can reproduce the clinical product at scale.

 

---

2. Biology: a novel pathway is a starting point, not a transaction thesis

Pulmonary fibrosis biology offers many intervention points: upstream ligands and receptors, intracellular signaling nodes, fibroblast activation, extracellular-matrix deposition and tissue-remodeling pathways. Some targets have extensive patient validation; others are supported mainly by human tissue, cellular systems and animal models. The BD task is to distinguish biological novelty from decision-grade translation. CK1δ/ε illustrates the distinction. A published preclinical study reported increased CK1δ/ε expression and activity in IPF lung tissue and showed that a tool inhibitor attenuated TGF-β-related fibrogenic responses in human cell systems and bleomycin models, including local administration in mice. That supports the pathway as a scientifically interesting downstream control node. It does not, by itself, establish human target engagement, patient dose, therapeutic window or clinical benefit for any particular development compound.

Mechanism questions that survive first contact

• Is the target active in the intended patient population and disease stage, not only in an injury model?
• Is there a proximal human biomarker that can connect deposited dose to target engagement?
• Can the molecule produce sufficient lung exposure without off-target, airway or systemic liabilities?
• Is the mechanism additive or complementary to approved oral therapy, with a practical combination path?

 

---

3. Clinical maturity: Phase 1 completion does not equal patient proof

For an inhaled small molecule, a healthy-volunteer single- and multiple-ascending-dose study can answer valuable questions: short-term tolerability, bronchospasm or irritation signals, systemic pharmacokinetics, dose escalation behavior and operational use of the formulation-device system. Those are meaningful de-risking steps. They do not demonstrate exposure in fibrotic lung, target engagement, chronic safety, adherence or anti-fibrotic efficacy.

Evidence layer	What it can establish	What remains unresolved
Healthy-volunteer SAD/MAD	Initial safety, plasma PK, dose escalation and device feasibility.	Diseased-lung deposition, patient PD, chronic tolerability and efficacy.
Short patient study	Airway tolerability, lung-relevant biomarkers and dose selection.	Durability, clinical benefit and broad population fit.
Controlled patient PoC	Direction and magnitude of effect against a prespecified comparator.	Confirmatory design, commercial scale and long-term benefit–risk.
Late-stage package	Regulatory benefit–risk and launch-level evidence.	Real-world adoption, adherence and lifecycle value.

 

Figure 2  |  Partnering readiness requires both patient evidence and execution readiness. Strong science in the lower-right quadrant is still an execution problem.

READ-THROUGH  The most valuable next experiment is usually the one that reduces a buyer’s largest uncertainty. For early inhaled assets, that is often a patient study with lung-relevant PD, exposure rationale and a pre-agreed progression rule—not another broad corporate deck.

 

---

4. The 2026 competitive benchmark is materially higher

An external partner will compare every new inhaled program against both the evolving oral standard and other lung-directed approaches. The correct comparator set is therefore broader than “same target” assets. It includes approved oral agents, inhaled reformulations, targeted anti-fibrotic mechanisms and fixed-dose combinations.

Public benchmark	Current public status	Strategic read-through
Jascayd® (nerandomilast)	FDA-approved for IPF and PPF.	A new oral efficacy/tolerability baseline; entrants need incremental benefit, combination value or lower treatment burden.
AP01 (inhaled pirfenidone)	Global Phase 2b MIST study in PPF; target enrollment completed in June 2026.	Patient-stage inhaled reformulation raises expectations for long-term lung function, usability and systemic-tolerability evidence.
AP02 (inhaled nintedanib)	Global Phase 2 AURA study in IPF initiated in March 2026.	Direct-to-lung delivery of an established agent tests whether lower systemic exposure can preserve efficacy.
AP03 (inhaled combination)	Phase 1 planned by end-2026.	A single inhaled dual-mechanism product could raise the bar for differentiation and device convenience.
BMS-986278 (LPA1 antagonist)	Phase 3 IPF program.	Novel targeted entrants already possess patient evidence; mechanism novelty alone cannot offset a weak clinical bridge.

 

A credible winning profile

• Clinically meaningful add-on or standalone value under a prespecified patient design.
• Evidence that lower systemic exposure produces an actual benefit, not only a pharmacokinetic observation.
• Acceptable administration time, emitted-dose reproducibility, cleaning burden and long-term adherence.
• A disciplined indication sequence: de-risk the lead disease before monetizing broad respiratory optionality.

POSITIONING RESET  The strongest story is rarely “the broadest anti-fibrotic.” It is a specific lung-localized product profile with a biomarker-led route to patient proof and a credible place in contemporary treatment.

 

---

5. IP, CMC and device execution determine whether scientific interest becomes a deal

For inhaled products, the transactable asset is not merely a chemical structure or target. It is a layered product system: compound, formulation, delivery device, manufacturing controls, clinical data and rights. A weakness in any one layer can compress valuation or force a staged transaction.

Diligence layer	Public signal may show	Partner-grade evidence required
Compound + use IP	A published or granted family around chemistry or pulmonary use.	Claim mapping for the clinical compound, salts, polymorphs, formulation, dose, combinations and priority markets; realistic FTO.
Formulation + device	A nebulized solution, suspension, MDI or DPI is described.	Commercial device selection, aerosol performance, emitted-dose reproducibility, extractables/leachables, human factors and change control.
CMC + supply	Clinical batches and stability summaries exist.	Scalable process, specifications, container-closure rationale, comparability strategy and supply-chain resilience.
Regulatory bridge	A non-US first-in-human study is complete.	FDA/EMA alignment, acceptability of prior data, chronic inhalation toxicology and an executable patient protocol.
Rights + data	Ownership appears in public registers or publications.	Clean chain of title; sublicensing/change-of-control rights; complete CSR, datasets, protocol history and reproducible study reports.

  FDA’s inhalation-product guidance underscores why this matters: product components, manufacturing process, controls and continuing performance characteristics are central CMC questions. Aerodynamic particle-size distribution, delivered dose, container-closure interactions and device performance are not packaging details to be solved after a license—they are part of the product’s evidence and IP architecture.

Transaction structure should mirror evidence maturity

Where patient proof is missing, an option-to-license or co-development structure can be more executable than a premium straight license. The partner can fund or share the first patient study; exercise can be tied to predefined safety, lung-PD and efficacy thresholds; economics can step up after proof; and follow-on mechanisms or indications can remain separate until they earn value.

DEAL DESIGN PRINCIPLE  Use staged economics to convert uncertainty into shared milestones. Do not ask a buyer to pay today for every theoretical indication, and do not give away a platform before the lead product validates it.

 

---

6. The partner-ready standard: a six-part test

A promising inhaled anti-fibrotic program becomes partner-ready when six questions can be answered with primary data and enforceable rights—not adjectives.

Dimension	Partner-ready question	Decision signal
Biology	Is the target causal and active in the intended patient population?	Human tissue + relevant models + translational biomarker.
Exposure	Does deposited dose create a usable lung exposure-to-effect relationship?	Lung-relevant PK/PD and dose rationale.
Clinical	Is there a safety window and a prespecified route to patient benefit?	Transparent data package and decision rule.
Product	Can formulation and device reproduce performance at commercial scale?	Controlled aerosol attributes, usability and CMC readiness.
IP / rights	Are product layers protected and rights transferable?	Claim map, FTO, chain of title and clean transaction authority.
Deal	Does structure allocate remaining uncertainty rationally?	Staged economics, clear governance and indication discipline.

 

Our conclusion

Inhaled anti-fibrotic programs deserve continued strategic attention. The route can create real therapeutic and commercial leverage, and the public pipeline shows that lung-directed delivery is moving into mainstream fibrosis development. But the same trend makes buyer discipline more important: novelty must become patient pharmacology; lower systemic exposure must become a measurable clinical advantage; and a promising molecule must become a reproducible drug–device product with defensible rights.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.